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a  b  s  t  r  a  c  t
Project:  This  study  investigated  the  in  vitro and  in  vivo  effectiveness  of  biogenic  selenium  nanoparticles
(Se  NPs),  biosynthesized  by  Bacillus  sp. MSh-1,  against  Leishmania  major  (MRHO/IR/75/ER).  Procedure:
The  3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyl-tetrazolium  bromide  (MTT)  assay  was  used  to  evaluate
the  cytotoxicity  effects  of the  biogenic  Se NPs  against  both  promastigote  and  amastigote  forms  of  L.
major.  In a separate  in vivo experiment,  we also  determined  the  preventive  and therapeutic  effects  of
biogenic  Se  NPs  in  BALB/c  mice  following  subcutaneous  infected  with  L.  major.  Results:  The  MTT  assays
showed  that  the  highest  toxicity  occurred  after  72  h  against  both  promastigote  and  amastigote  forms
of  L.  major.  The  cytotoxicity  of  Se  NPs  was  higher  at all  incubation  times  (24, 48, and  72 h) against  the
promastigote  than  the  amastigote  form  (p < 0.05).  The  50%  inhibitory  concentrations  (IC50) of  the  Se NPs
were  1.62  ±  0.6  and  4.4  ±  0.6 g ml−1 against  the promastigote  and  amastigote  forms,  respectively,  aftereishmania major
nti-leishmanial effect
a  72-h  incubation  period.  Apoptosis  assays  showed  DNA  fragmentation  in promastigotes  treated  with  Se
NPs. In an  animal  challenge,  prophylactic  doses  of  biogenic  Se  NPs  delayed  the  development  of  localized
cutaneous  lesions.  Moreover,  daily  administration  of  Se  NPs  (5  or 10 mg  kg−1 day−1) in similarly  infected
BALB/c  mice  that  had  not  received  prophylactic  doses  of  Se  NPs  also  abolished  the  localized  lesions  after
14 days.  Conclusion:  Based  on  these  in  vitro  and  in  vivo  studies,  biogenic  Se NPs  can  be considered  as  a
novel  therapeutic  agent  for treatment  of the localized  lesions  typical  of cutaneous  leishmaniasis.ntroduction
Leishmaniasis is a disease caused by obligate and intracellular
arasites belonging to the genus Leishmania [1]. It is transmitted by
he bite of certain species of sandﬂy (subfamily Phlebotominae) and
auses a wide spectrum of disorders, ranging from self-limited skin
isease to diffuse or severe visceral disease [2]. Different preventive
fforts, such as control of the sandﬂy insect vector or vaccination
gainst Leishmania, have been applied to limit leishmaniasis, but
hese efforts have not yet been completely successful [3,4].
Currently, chemotherapy remains the most efﬁcient way  to
reat leishmaniasis [5,6]. The pentavalent antimonials, such as
odium stibogluconate (Pentostam®) and meglumine antimoniate
Glucantine®), are the ﬁrst line of medications for leishmaniasis
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diseases [7,8]. Unfortunately, these antimony-based drugs have
unwanted side effects, such as pain at the injection site, which
decreases their acceptability by patients [9,10]. Consequently, a
constant need exists to ﬁnd potent anti-Leishmania compounds or
to develop novel treatment methods to combat this disease. Leish-
maniasis presently affects about 12 million persons globally, and is
particularly prevalent in subtropical and tropical regions, making
it a serious public health problem [11,12].
The biomedical applications of nanomaterials as biosensors,
drug carriers, anticancer therapies, and antimicrobial agents have
been rapidly growing in recent years [13,14]. One attractive
component for incorporation into antimicrobial nanomaterials is
selenium, a micronutrient element with broad functions in biolog-
ical systems. Selenium ions have antioxidant, cancer preventing,
and antiviral activities [15–17] and also appear to improve the
immune response of hosts against various species of bacteria and
viral antigens [18]. Elemental selenium (Se0) is an insoluble metal-
loid compound and can be chemically or biologically fabricated at
nano-scale [19,20]. In recent years, selenium nanoparticles (Se NPs)
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ave drawn the attention of researchers due to their outstanding
iological properties [21].
Biosyntheses of Se NPs have been recently developed as novel,
lean, non-toxic, and eco-friendly techniques [13]. The generated
e NPs show lower toxicity than selenium oxyanions, such as
eO3−2 and SeO4−2 [22,23]. However, to the best of our knowledge,
he available literature contains no reports on the evaluation of Se
Ps as a treatment for cutaneous leishmaniasis. Therefore, the aim
f the present study was to prepare and purify Se NPs using our pre-
iously described biogenic method [24] and to examine the effects
f these NPs on the proliferation of promastigote and amastigote
orms of Leishmania major using an in vitro MTT  assay. Cutaneous
eishmaniasis was also experimentally induced in BALB/c mice for
urther testing of the preventive and therapeutic effectiveness of
iogenic Se NPs against L. major infection in this animal model.
aterials and methods
iosynthesis of Se NPs
The Se NPs were biosynthesized as described in our previous
tudy [24]. Brieﬂy, nutrient broth medium (NB) was prepared, ster-
lized, and supplemented with a sterile solution of SeO2 (1.26 mM)
Merck, Germany). A fresh inoculum (1%, v/v) of Bacillus sp. MSh-
 (OD600, 0.1) was added to the culture medium, the ﬂasks were
lugged with cotton, and the culture was incubated aerobically at
0 ◦C in a shaker incubator (150 rpm). After 14 h, the bacterial cells
nd the formed Se NPs were removed from the culture medium by
entrifugation at 4000 × g for 10 min. The precipitated Se0 NPs are
ed, and this color serves as a provisional marker that the microor-
anism is reducing the Se4+ ions to Se NPs. The resulting pellets
ere frozen by adding liquid nitrogen and then disrupted with a
ortar and pestle. The Se NPs were isolated from cell debris using
n n-octyl alcohol water extraction system [24]. For further biolog-
cal experiments, the spherical and amorphous Se NPs (80–220 nm)
ere re-suspended in sterile NaCl solution (0.9%) and stored at 4 ◦C.
arasite and culture procedure
L. major (MRHO/IR/76/ER) was purchased from the Pasteur Insti-
ute of Iran (Tehran, Iran) and cultured in RPMI 1640 medium
upplemented with 10% (v/v) heat-inactivated fetal calf serum
Gibco, United States), 100 units ml−1 penicillin, and 100 g ml−1
treptomycin (Sigma, United Kingdom) at 27 ◦C in a CO2 incubator
5% CO2 and 95% relative humidity).
n vitro anti-proliferation effect of Se NPs against L. major
romastigotes
The L. major promastigotes in the logarithmic phase were col-
ected and suspended in sterile RPMI 1640 medium supplemented
ith 10% (v/v) heat-inactivated fetal calf serum (1 × 106 cells ml−1).
liquots of this suspension (100 l) were aseptically dispensed into
6-well tissue culture plates and pre-incubated at 27 ◦C for 1 h.
tandard solutions of Se NPs (2–300 g ml−1) were prepared in
PMI 1640, and 100 l aliquots were added to the plates to give ﬁnal
oncentrations of 1–150 g ml−1. Control wells contained 100 l of
PMI 1640 only. The plates were incubated at 27 ◦C in a CO2 incu-
ator (5% CO2 and 95% relative humidity) for 24, 48, and 72 h, and
hen 20 l of RPMI 1640 medium containing 5 mg  ml−1 of MTT  [3-
4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide]
as added to each well and incubated for 4 h. The medium was
emoved by centrifugation (2000 × g, 10 min) and 100 l of DMSO
as added to the cell pellets. The optical density of the purple color
ue to formazan formation was read at 570 nm.  The 50% inhibitoryedicine and Biology 27 (2013) 203– 207
concentrations (IC50) were determined by linear regression analy-
sis. All assays were performed in triplicate.
Apoptosis–DNA ladder assay
Qualitative analysis of total genomic DNA fragmentation was
performed by agarose gel electrophoresis. Brieﬂy, promastigotes
(2 × 106 cells) were incubated with different concentrations of Se
NPs (0, 1, 50, and 150 g ml−1) at 27 ◦C in a CO2 incubator (5%
CO2 and 95% relative humidity) for 24 h. An apoptotic DNA ladder
kit (Roche, Germany) was then used to extract DNA from either
apoptosis-induced or noninduced cells, according to the manu-
facturer’s instructions. The extracted DNA samples (10 g) were
electrophoresed in 1.5% agarose gels at 75 V for 1.5 h, visualized
with a UV transilluminator, and photographed.
Se NP toxicity in macrophages
Peritoneal macrophages were harvested from male BALB/c mice
(Pasteur Institute of Iran, Tehran, Iran). After an intraperitoneal
injection of 2 ml  of RPMI1640, the peritoneal macrophages were
evacuated under aseptic conditions. The cells were dispensed into
culture ﬂasks containing RPMI 1640 medium supplemented with
10% heat-inactivated fetal calf serum (FCS), 25 mM HEPES buffer,
and 2 mM l-glutamine (Life Technologies, France). Aliquots (100 l)
of the macrophage cultures (1 × 105 cell ml−1) were plated in 96-
well plate wells. After the cells had adhered, the culture medium
was discarded and replaced with fresh culture medium (100 l)
containing different amounts of Se NPs (0–150 g ml−1). After
24, 48, and 72 h of culture, the viability of the macrophages was
checked using the MTT  assay and the IC50 was  determined by linear
regression.
Cytotoxicity of Se NPs in intramacrophage amastigotes
Infected macrophages (10 ± 3 amastigotes per macrophage)
were obtained by adding promastigote forms of L. major in the sta-
tionary phase to macrophage cultures in 8-well culture chamber
slides (Lab-tek Nunc Inc.) at a ratio of 10 parasites per macrophage.
The mixtures were incubated in a CO2 incubator (37 ◦C, 5% CO2,
and 95% relative humidity) for 24 h, to allow infection of the
macrophages by the promastigotes. Excess parasites were then
removed by washing, and the cells were incubated for 24 h in cul-
ture medium alone. This medium was discarded and the cells were
incubated at 37 ◦C for 72 h in fresh medium that contained Se NPs
at different concentrations (0–150 g ml−1). During and following
the incubation period (24, 48, and 72 h), the medium and the cham-
bers were removed and the slides were ﬁxed with methanol and
Giemsa-stained. The number of amastigotes per 100 macrophages
on each coverslip was  determined with a microscope. The IC50
(g ml−1) was  determined by linear regression and comparison to
untreated controls.
In vivo evaluation of Se NPs against L. major infection
Male BALB/c mice (body weight 20–22 g; n = 40) were purchased
from the Pasteur Institute of Iran (Tehran, Iran) and housed in plas-
tic cages in a colony room at a controlled temperature (22 ± 1 ◦C)
and humidity (50 ± 10%) under a 12/12 h light/dark cycle. The
experimental procedures carried out in this study were in com-
pliance with the guidelines of the Tehran University of Medical
Science (Tehran, Iran) for the care and use of laboratory animals.
The L. major (MRHO/IR/76/ER) used for infection was cultured in
RPMI 1640 medium supplemented with 10% (v/v) fetal calf serum
(FCS) at 27 ◦C in a CO2 incubator (5% CO2 and 95% relative humidity).
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Fig. 2. Fragmentation analysis of DNA by agarose gel electrophoresis after 24 h incu-
bation of Leishmania major with different concentration of Se NPs. (lane M): size
marker, (lane C): positive control from the kit, lanes 2–4: fragmentation in genomic
trations of Se NPs (Fig. 3). When peritoneal macrophages were
incubated for 24, 48, and 72 h, in the absence and presence of differ-


































l)ig. 1. The viability of Leishmania major promastigotes in the presence of various
oncentrations of the biogenic Se NPs following different incubation periods. Data
re  expressed as the mean ± SD (n = 3).
The mice were divided into ﬁve groups. Groups 1 and 2 were
ntraperitoneally administered Se NPs at 5 and 10 mg  kg−1 day−1,
espectively for 14 days. The mice in these groups were then
ubcutaneously infected with 0.1 ml  of stationary phase promastig-
tes (1 × 107 ml−1). The mice in groups 3 did not receive Se NPs
nd considered as control, Mice in group 4, and group 5 were
ubcutaneously infected with the same amount (0.1 ml)  of pro-
astigotes (1 × 107 ml−1) at ﬁrst, then after the appearance of
praised lesions they were intraperitoneally injected with Se NPs
t 5 and 10 mg  kg−1 day−1, respectively for 14 days. All animals
ere housed under standard conditions for six weeks to allow the
ormation of visible upraised lesions. After this period, the lesions
ere monitored for a further 21 days and the mean diameters were
easured at different intervals.
tatistical analysis
All data represent the means ± standard deviations (SD) of three
ndependent experiments. Data were analyzed by one-way ANOVA
ests and Scheffe post hoc tests, using SPSS 15 for Windows. A p-
alue less than 0.05 was considered signiﬁcant.
esults and discussion
he cytotoxicity of biogenic Se NPs to the promastigote form of L.
ajor
The physical, chemical, and biological properties of nanoma-
erials are considerably different from macroscopic and even
icroscopic ones [25]. In this study, Se NPs exhibited different bio-
ogical activities and low toxicity [21,26]; therefore, we were able
o evaluate the effects of Se NPs on the two parasitic forms of L.
ajor using both in vitro and in vivo methods. The in vitro efﬁcacy
f Se NPs against the promastigotes was determined after differ-
nt exposure times (Fig. 1). Promastigote proliferation decreased
n the presence of Se NPs in a time-dependent manner (Fig. 1), with
he highest cytotoxicity observed after 72 h of exposure. The IC50
as 1.62 ± 0.6 g ml−1 for promastigotes incubated with Se NPs for
2 h.
Different living parasites, such as Trypanosoma, Leishmania,
nd Kinetoplastida,  as well as other higher organisms, need trace
mounts of selenium ions [27]. However, high in vitro concen-
rations of this vital compound were toxic to the promastigotes
p < 0.05) and caused some biochemical hallmarks, such as DNA
ragmentation, in the parasite. DNA fragmentation is one of the
ost important changes that occur during apoptotic cell death [28].DNA  of promastigotes (lane 1): 0 g ml−1, (lane 2): 1 g ml−1, (lane 3): 50 g ml−1,
(lane 4): 150 g ml−1.
The DNA fragmentation in the promastigotes in the absence and
the presence of Se NPs is shown in Fig. 2. Genomic DNA samples
were isolated from promastigotes exposed to Se NPs (0, 1, 50, and
150 g ml−1) for 24 h. Fragmentation was observed in the genomic
DNA of the promastigotes (lanes 2–4 in Fig. 2) at all tested concen-
trations of Se NPs, and showed a comparable pattern to that of the
positive control ladder of the commercial kit (lane C in Fig. 2). The
fragment sizes of DNA isolated from promastigotes treated with
Se NPs were between 100 and 1000 base pairs (Fig. 2). In contrast,
no signiﬁcant DNA fragmentation was  observed for promastigotes
incubated in the absence of Se NPs (lane 1 in Fig. 2). A similar tox-
icity effect of Se NPs on genomic DNA was  previously reported for
human melanoma cells treated with chemically synthesized Se NPs
[29]. Our results have further conﬁrmed the ability of biogenic Se
NPs to induce apoptosis in another form of eukaryotic cell, the L.
major promastigote.
General cytotoxicity of biogenic Se NPs to macrophage cells
Our cytotoxicity analysis of peritoneal macrophages showed a
dose-dependent response that increased with increasing concen-Se NPs (μg /ml)
Fig. 3. The cytotoxicity effects of the Se NPs on peritoneal macrophages isolated
from BALB/c mice. Data are expressed as the mean ± SD (n = 3).















































































































Fig. 5. Therapeutic effects of Se NPs on the lesion sizes (mm) of localized cuta-
neous leishmaniasis induced by Leishmania major in BALB/c mice. Two weeks before
challenging with promastigotes: Group 1: Mice were intraperitoneally received
SeNPs with 5 mg  kg−1 day−1 and Group 2: which received SeNPs intraperitoneally at
10  mg kg−1 day−1. Group 3: mice were not received SeNPs but infected by L. major
and considered as control. After upraised lesions appeared: groups 4 and 5 received
intraperitoneally 5 and 10 mg kg−1 day−1 of Se NPs, respectively for 14 days. Data
are expressed as the mean ± SD (n = 8). Error bars were omitted for clarity of theig. 4. The effects of Se NPs on Leishmania major amastigotes incubated for different
eriods. Data are expressed as the mean ± SD (n = 3).
fter 72 h, especially at the higher concentrations. The IC50 of the
iogenic Se NPs was 10.5 ± 0.6 g ml−1.
he cytotoxicity of biogenic Se NPs to the intramacrophage
mastigote form of L. major
Biogenic Se NPs prepared by Bacillus sp. MSh-1 showed sub-
tantial cytotoxicity to the intracellular amastigotes after 24, 48,
nd 72 h exposure (Fig. 4). The IC50 for Se NPs against this para-
itic form of L. major after 72 h was 4.4 ± 0.6 g ml−1. After 72 h of
ncubation, a low concentration of biogenic Se NPs (2.5 g ml−1)
igniﬁcantly decreased the viability of intramacrophage amastig-
tes (p < 0.05) (Fig. 4). In contrast, no appreciable toxicity was
bserved for macrophages exposed to the biogenic Se NPs at a
oncentration of 2.5 g ml−1 (Fig. 3).
he preventive and therapeutic effects of Se NPs in mice infected
ith L. major
Sub-toxic doses of biogenic Se NPs (5 and 10 mg  kg−1 day−1)
ere chosen to evaluate their preventive and therapeutic effects in
ALB/c mice that had been cutaneously infected by the promastig-
te form of L. major.  Our previous studies on the toxicity of Se NPs
n BALB/c mice showed that these NPs at the chosen doses (5 and
0 mg kg−1 day−1) showed no toxicity effects on the tested animals
nd could be considered safe (unpublished data). Therefore, these
oses were used for in vivo evaluation of Se NPs against cutaneous
eishmaniasis in BALB/c mice. Approximately six weeks after injec-
ion of the promastigotes, lesions had developed in all groups. The
ean diameters of lesions in groups 1 and 2, which had received
reventive doses (5 and 10 mg  kg−1) of Se NPs for 14 days, were
igniﬁcantly smaller than those of the untreated control group 3
p < 0.05) (Fig. 5). Therefore, if Se NPs were administered before
xposure of animals to L. major promastigotes, this could result in
 considerable reduction in the severity of outbreak of cutaneous
eishmaniasis. This suggests that selenium and its related com-
ounds can be used for prophylaxis against various pathogens by
nduction of an immune response [30]. However, the mean diam-
ter of lesions in group 2 was not signiﬁcantly different from that
f group 1 (p > 0.05) (Fig. 5).
It has previously been demonstrated that oral administration of
e NPs can shift the immune response of BALB/C mice toward a T
elper 1 type response [31]. Therefore, the limited lesion devel-
pment in Se NP-treated mice may  be related to cell mediated
mmune responses (Th1 type) and the pretreatment of infected
ALB/c mice with Se NPs at 5 or 10 mg  kg−1 day−1 could lead to
 similar prophylactic effect. When Se NPs were intraperitoneally
njected at the same doses (5 or 10 mg  kg−1 day−1) into infected
ALB/c mice (groups 4 and 5), the post treatment with biogenicgraphs.
Se NPs not only signiﬁcantly (p > 0.05) decreased the cutaneous
lesion sizes compared to the control group 3, but it also com-
pletely abolished these lesions in BALB/c mice (Fig. 5). The mean
diameters of the lesions in groups 4 and 5, which received 5 or
10 mg  kg−1 day−1 of Se NPs, respectively, were not signiﬁcantly
different from each other (p > 0.05). Lesions in both groups van-
ished after 14 days (Fig. 5). We evaluated the cytotoxicity of Se
NPs prepared by Bacillus sp. MSh-1 against the promastigote and
amastigote forms of L. major in an in vitro assay. We  also evalu-
ated Se NP effects on the proliferation of peritoneal macrophage
cells. The IC50 values obtained for Se NPs, in increasing order, were:
promastigotes > amastigotes > macrophages, which indicated that
the toxicity of Se NPs was  higher against the promastigote form
of L. major than against the amastigote form or against perit-
oneal macrophage cells (p < 0.05). The reasons for this difference
in toxicity may be due to the phagolysosomal membrane of the
macrophage, which would decrease the penetration of Se NPs into
the macrophage cells and decrease the concentrations of Se NPs
around the intramacrophage amastigotes.
The efﬁcacy of biogenic Se NPs as a pretreatment or treatment
for cutaneous leishmaniasis was further evaluated in vivo using a
challenge test in infected BALB/c mice.
The biogenic Se NPs could signiﬁcantly limit the develop-
ment of lesions when these NPs were prescribed as a prophylaxis
regime. They could also successfully eliminate cutaneous lesions
in BALB/c mice infected by L. major when Se NPs were admin-
istered after the development of cutaneous lesions. It should be
noted that no leishmaniasis drugs were prescribed during this
investigation.
Conclusion
To sum up the results of present work, it can be deduced that Se
NPs can inhibit the proliferation of the promastigote and amastig-
ote forms of L. major and limit localized cutaneous leishmaniasis in
animal model. Based on current in vitro and in vivo studies, biogenic
Se NPs can be considered as a novel therapeutic agent for treat-
ment of the localized lesions typical of cutaneous leishmaniasis.
But still more studies are needed to explore the exact mechanisms
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